Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC)
Carles Codony(Institut d'Investigació Biomédica de Bellvitge), Rafael Rosell(Hospital Universitario Dexeus)
Cited by 49
Related Papers
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
|Journal of Clinical Oncology|2004|1.7k
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2017|1.2k
Non-small-cell lung cancer
|Nature Reviews Disease Primers|2015|1.1k
Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
|Nature Communications|2017|182